Diseases [C] » Neoplasms [C04] » Precancerous Conditions
Description
Pathological conditions that tend eventually to become malignant. MeSH
Hierarchy View
Subtype Terms (10)
Aberrant Crypt Foci
2 drugs (1 approved, 1 experimental)
Barrett Esophagus
36 drugs (23 approved, 13 experimental)
Keratosis, Actinic
71 drugs (39 approved, 32 experimental)
Leukoplakia
4 approved drugs
Lymphomatoid Granulomatosis
80 drugs (54 approved, 26 experimental)
Preleukemia
10 drugs (7 approved, 3 experimental)
Smoldering Multiple Myeloma
36 drugs (26 approved, 10 experimental)
Uterine Cervical Dysplasia
27 drugs (13 approved, 14 experimental)
Xeroderma Pigmentosum
3 approved drugs
Phase 4 Indicated Drugs (1)
Phase 3 Indicated Drugs (28)
Phase 1 Indicated Drugs (26)
Other Experimental Indicated Drugs (17)
Organization Involved with Phase 3 Indications (31)
Organization Involved with Phase 2 Indications (54)
AIDS and Cancer Specimen Resource
British Columbia Cancer Agency
Cancer Biotherapy Research Group
Cancer Treatment Centers of America
Case Western Reserve University
Chao Family Comprehensive Cancer Center
Guangdong Provincial Hospital of Traditional Chinese Medicine
Hoag Memorial Hospital Presbyterian
Hoosier Cancer Research Network
National Institutes of Health (NIH)
Oregon Health and Science University
Shaanxi University of Chinese Medicine
Shanghai Yueyang Integrated Medicine Hospital
Organization Involved with Phase 1 Indications (18)
Organization Involved with Other Experimental Indications (7)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.